Axogen, Inc. announced that management will participate in three investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Leerink Global Healthcare Conference (March 9), and The Citizens Life Sciences Conference (March 10). The company will present and hold 1x1 investor meetings at these events, with webcasts available on its investor relations website.

Axogen, Inc. (Nasdaq: AXGN), a peripheral nerve repair solutions company, announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, followed by a management conference call and webcast at 8:00 a.m. ET. The company invites investors to participate via phone or live webcast.

Axogen, Inc. announced an upsized underwritten public offering of 4 million shares at $31.00 per share, expected to raise approximately $124 million in gross proceeds. The company plans to use the net proceeds to pay off its term loan facility with Oberland Capital, along with working capital and capital expenditures. The offering is expected to close on January 23, 2026.

Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.

Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.

The Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.

The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will report its 2024 fourth quarter and full year financial results on February 25, 2025. The company will host an investment-community conference call and webcast to discuss the results.

Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a company known for its development in biosensors. The acquisition is expected to strengthen Bruker's position in the pharma and biotech industries by leveraging its leading high-throughput Surface Plasmon Resonance portfolio and Dynamic Biosensors' unique instruments.

Bruker Corporation's growth is backed by strong sales in its X-Ray and Nano Analytics businesses, as well as increasing customer demand for its preclinical MRI systems. However, the company faces challenges from macroeconomic pressures and currency fluctuations.

The article discusses how September has historically been a weak month for the stock market, but this year the S&P 500, Dow, and Nasdaq have gained over 1% so far, breaking a 5-year trend. The author recommends buying three breakout stocks that could take advantage of the broader market's upward movement: Bioventus (BVS), Great Lakes Dredge & Dock (GLDD), and AxoGen (AXGN).

Inogen is well-positioned for growth in the portable oxygen concentrator (POC) market, with a strong product portfolio and solid Q2 results. However, it faces stiff competition and forex volatility. The company's stock has outperformed the industry and the S&P 500 year-to-date.